Why cap it at 81.5? Will go higher with its balance sheet and half year results. $1.00 upwards is not out of the question. It's been good fun holding this stock.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
